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Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 
Mutations
To the editor: Familial hypocalciuric hypercal-
cemia is a genetically heterogeneous disorder 
with three variants: types 1, 2, and 3. Type 1 is 
caused by calcium-sensing receptor (CASR) muta-
tions,1 and type 2 is caused by guanine nucleo-
tide–binding protein (G-protein) subunit α11 
(GNA11) mutations.2 Type 3, which is the most 
severe variant clinically, is caused by adaptor-
related protein complex 2 (AP2), sigma 1 subunit 
(AP2S1) heterozygous mutations. AP2S1 muta-
tions cause Arg15Cys, Arg15His, and Arg15Leu 
substitutions, and the mutant AP2-sigma proteins 
result in impaired calcium-sensing receptor–
mediated signal transduction.3,4
There is currently no effective therapy for 
familial hypocalciuric hypercalcemia type 3. 
We therefore evaluated the usefulness of cinacal-
cet, a licensed calcium-sensing receptor alloste-
ric activator,5 in correcting signaling defects due 
to AP2S1 mutations and in ameliorating symptom-
atic hypercalcemia.
We evaluated three previously unreported 
cases of familial hypocalciuric hypercalcemia 
type 3. Each of the three probands had an AP2S1 
mutation causing an Arg15Cys, Arg15His, or 
Arg15Leu substitution (Fig. 1A). The probands 
included a 34-year-old woman who had a 12-year 
history of hypercalcemia. She presented with 
fatigue, headaches, and persistent generalized 
aches that did not resolve after parathyroidec-
tomy. In addition, a 22-year-old man presented 
with hypercalcemia, fatigue, and generalized rib 
pain, and a 52-year-old woman who had an ap-
proximately 20-year history of hypercalcemia pre-
sented with headaches, abdominal pain, vomit-
ing, fatigue, and musculoskeletal pain that did 
not resolve after pamidronate infusion or para-
thyroidectomy (Fig. 1A and 1B).
The in vitro effects of cinacalcet on the sig-
naling responses of cells expressing the calcium-
sensing receptor and familial hypocalciuric hyper-
calcemia type 3–associated AP2-sigma mutants 
were assessed by measurement of intracellular 
calcium concentrations and of the activity of the 
mitogen-activated protein kinase (MAPK)–serum 
response element reporter in response to altera-
tions in extracellular calcium (see the Methods 
section in the Supplementary Appendix, avail-
able with the full text of this letter at NEJM.org). 
Cinacalcet (at a concentration of 10 nM) corrected 
the abnormal intracellular calcium signaling and 
MAPK responses to extracellular calcium in cells 
expressing the Cys15, His15, or Leu15 AP2-sigma 
mutants (Fig. S1 and S2 in the Supplementary 
Appendix).
Oral cinacalcet (at a dose of 30 to 60 mg daily) 
was administered to the three probands with 
familial hypocalciuric hypercalcemia type 3 over 
a 33-to-45-month period. This treatment led to 
more than 20% reductions in serum calcium 
concentrations (Fig. 1B) and abatement of symp-
toms. Cinacalcet also increased serum phosphate 
concentrations and reduced serum parathyroid 
hormone concentrations, although these values 
remained within the normal range (Fig. 1B).
Adverse effects such as nausea, vomiting, and 
hypocalcemia did not develop in any of the pro-
bands. However, long-term surveillance will be 
required to assess safety and monitor for hypo-
calcemia.
Our results show that cinacalcet-mediated 
allosteric modulation of the calcium-sensing re-
ceptor can correct the loss of function of AP2S1 
mutations. In addition, in the short term, cina-
calcet can reduce the symptoms of familial hypo-
calciuric hypercalcemia type 3 associated with 
all three AP2S1 mutations.
Figure 1 (facing page). Cinacalcet for Hypercalcemia 
Associated with AP2S1 Mutations.
Panel A shows the clinical and biochemical findings at 
presentation in three unrelated probands with familial 
hypocalciuric hypercalcemia who had heterozygous 
adaptor-related protein complex 2 (AP2), sigma 1 sub-
unit (AP2S1) mutations resulting in Arg15Cys, Arg15His, 
or Arg15Leu substitutions in the AP2-sigma mutant pro-
teins. Reference ranges are from Nesbit et al.2 Panel B 
shows the effect of cinacalcet on serum concentrations 
of calcium, phosphate, and parathyroid hormone in the 
three probands. Vertical dashed lines indicate initiation 
of cinacalcet (CIN) therapy, pamidronate (PMD) infu-
sion, or parathyroidectomy (PTX). Shaded gray areas 
indicate reference ranges.
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A
B
Sex
Age at presentation — yr
Family history of hypercalcemia
Associated clinical features
Serum measurements
Calcium — mmol/liter
Ionized
Albumin-adjusted 
Phosphate — mmol/liter 
Alkaline phosphatase
Total — U/liter
Bone-specific — µg/liter 
Magnesium — mmol/liter 
Parathyroid hormone
Base units
SI units
Urinary calcium-to-creatinine clearance ratio
AP2S1 mutation
Proband 1 Proband 3Proband 2
Proband 1 (Arg15Cys) Proband 3 (Arg15Leu)Proband 2 (Arg15His)
Variable
Female
22 
Yes
Fatigue, headaches,
generalized musculo-
skeletal pain
1.72
 —
1.00 
55.0
—
0.97
28.5 
—
0.001
Arg15Cys
Reference Range
 
  
 
1.10–1.30
2.10–2.60
0.70–1.40 
30–130
3.7–20.9
0.70–1.40 
10–65 ng/liter
1.3–7.6 pmol/liter
>0.02
Male
22
Yes
Fatigue, rib pain
1.53
 —
0.80 
—
20.6
—
65.1 
—
0.002
Arg15His
Female
32
No
Fatigue, headaches, vomiting,
abdominal and musculo-
skeletal pain
—
3.07 
0.95 
81.0
—
0.98
—
6.2
0.001
Arg15Leu
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